Lymphangioleiomyomatosis and Pulmonary Disease in TSC

Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics

Volumn , Issue , 2010, Pages 345-368

  McCormack, Francis X ^a   Henske, Elizabeth P ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Lymphangioleiomyomatosis; Multinodular multifocal pneumocyte hyperplasia; Pleurodesis; Sporadic lymphangioleiomyomatosis; Tuberous sclerosis complex; Vascular endothelial growth factor D

Indexed keywords

EID: 84884525752     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630073.ch17     Document Type: Chapter

References (105)

1. McCormack, F.X. (2008) Lymphangioleiomyomatosis: a clinical updat., 133, 507-516.
2. Lutembacher, R. (1918) Dysembryomes metatypiques des reins; carcinose submiliaire aigue du poumon avec emphyseme generalise et double pneumothorax. Ann. Med, 5, 435-450.
3. von Stossel, E. (1937) Uber muskulare Cirrhose der Lunge (Muscular cirrhosis of the lung). Beitr. Klin. Tuberk, 90, 432-442.
4. Cornog, J.L., Jr. and Enterline, H.T. (1966) Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytom., 19, 1909-1930.
5. Corrin, B., Leibow, A.A., and Friedman, P.J. (1975) Pulmonary lymphangiomyomatosis: a review. Am. J. Pathol, 79, 348-382.
6. Costello, L.C., Hartman, T.E., and Ryu, J.H. (2000) High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin. Proc, 75, 591-594.
7. Franz, D.N., Brody, A., Meyer, C., Leonard, J., Chuck, G., Dabora, S., Sethuraman, G., Colby, T.V., Kwiatkowski, D.J., and McCormack, F.X. (2001) Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am. J. Respir. Crit. Care Med, 164, 661-668.
8. Moss, J., Avila, N.A., Barnes, P.M., Litzenberger, R.A., Bechtle, J., Brooks, P.G., Hedin, C.J., Hunsberger, S., and Kristof, A.S. (2001) Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am. J. Respir. Crit. Care Med, 164, 669-671.
9. Osborne, J.P., Fryer, A., and Webb, D. (1991) Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci, 615, 125-127.
10. O'Callaghan, F.J., Shiell, A.W., Osborne, J.P., and Martyn, C.N. (1998) Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet, 351, 1490.
11. Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., Valeyre, D., and Cordier, J.F. (1999) Pulmonary lymphangioleiomyomatosi., 78, 321-337.
12. Ryu, J.H., Moss, J., Beck, G.J., Lee, J.C., Brown, K.K., Chapman, J.T., Finlay, G.A., Olson, E.J., Ruoss, S.J., Maurer, J.R., Raffin, T.A., Peavy, H.H., McCarthy, K., Taveira-Dasilva, A., McCormack, F.X., Avila, N.A., Decastro, R.M., Jacobs, S.S., Stylianou, M., and Fanburg, B.L. (2006) The NHLBI Lymphangioleiomyomatosis Registry: characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med, 173, 105-111.
13. Johnson, S.R. and Tattersfield, A.E.(2000) Clinical experience of lymphangioleiomyomatosis in the UK. Thorax, 55, 1052-1057.
14. Hayashida, M., Seyama, K., Inoue, Y., Fujimoto, K., and Kubo, K. (2007) The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factor., 12, 523-530.
15. Aubry, M.C., Myers, J.L., Ryu, J.H., Henske, E.P., Logginidou, H., Jalal, S.M., and Tazelaar, H.D. (2000) Pulmonary lymphangioleiomyomatosis in a man. Am. J. Respir. Crit. Care Med., 162, 749-752.
16. Miyake, M., Tateishi, U., Maeda, T., Kusumoto, M., Satake, M., Arai, Y., and Sugimura, K. (2005) Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat. Med, 23, 525-527.
17. Kim, N.R., Chung, M.P., Park, C.K., Lee, K.S., and Han, J. (2003) Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol. Int, 53, 231-235.
18. Schiavina, M., Di Scioscio,V., Contini, P., Cavazza, A., Fabiani, A., Barberis, M., Bini, A., Altimari, A., Cooke, R.M., Grigioni,W.F., and D'Errico-Grigioni, A. (2007) Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am. J. Respir. Crit. Care Med., 176, 96-98.
19. Johnson, S.R., Whale, C.I., Hubbard, R.B., Lewis, S.A., and Tattersfield, A.E. (2004) Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax, 59, 800-803.
20. Kitaichi, M., Nishimura, K., Itoh, H., and Izumi, T. (1995) Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med, 151, 527-533.
21. Oh, Y.M., Mo, E.K., Jang, S.H., Yoo, C.G., Kim, Y.W., Seo, J.W., Han, S.K., Im, J.G., and Shim, Y.S. (1999) Pulmonary lymphangioleiomyomatosis in Korea. Thorax, 54, 618-621.
22. Almoosa, K.F., Ryu, J.H., Mendez, J., Huggins, J.T., Young, L.R., Sullivan, E.J., Maurer, J., McCormack, F.X., and Sahn, S.A. (2006) Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest, 129, 1274-1281.
23. Carrington, C.B., Cugell, D.W., Gaensler, E.A., Marks, A., Redding, R.A., Schaaf, J.T., and Tomasian, A. (1977) Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am. Rev. Respir. Dis, 116, 977-995.
24. Matsumoto, Y., Horiba, K., Usuki, J., Chu, S.C., Ferrans, V.J., and Moss, J. (1999) Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol, 21, 327-336.
25. Hoon, V., Thung, S.N., Kaneko, M., and Unger, P.D. (1994) HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch. Pathol. Lab. Med, 118, 732-734.
26. McCarty, K.S., Jr., Mossler, J.A., McLelland, R., and Sieker, H.O. (1980) Pulmonary lymphangiomyomatosis responsive to progesterone. N. Engl. J. Med, 303, 1461-1465.
27. Colley, M.H., Geppert, E., and Franklin, W.A. (1989) Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am. J. Surg. Pathol, 13, 803-807.
28. Berger, U., Khaghani, A., Pomerance, A., Yacoub, M.H., and Coombes, R.C. (1990) Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am. J. Clin. Pathol, 93, 609-614.
29. Kumasaka, T., Seyama, K., Mitani, K., Sato, T., Souma, S., Kondo, T., Hayashi, S., Minami, M., Uekusa, T., Fukuchi, Y., and Suda, K. (2004) Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am. J. Surg. Pathol., 28, 1007-1016.
30. Seyama, K., Kumasaka, T., Souma, S., Sato, T., Kurihara, M., Mitani, K., Tominaga, S., and Fukuchi, Y. (2006) Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat. Res. Biol, 4, 143-152.
31. Young, L.R., Inoue, Y., and McCormack, F.X. (2008) Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N. Engl. J. Med, 358, 199-200.
32. Muir, T.E., Leslie, K.O., Popper, H., Kitaichi, M., Gagne, E., Emelin, J.K., Vinters, H.V., and Colby, T.V. (1998) Micronodular pneumocyte hyperplasia. Am. J. Surg. Pathol, 22, 465-472.
33. Kobashi, Y., Sugiu, T., Mouri, K., Irei, T., Nakata, M., and Oka, M. (2008) Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. Respirology, 13, 1076-1081.
34. Kobashi, Y., Sugiu, T., Mouri, K., Irei, T., Nakata, M., and Oka, M. (2008) Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia. Jpn. J. Clin. Oncol, 38, 451-454.
35. Taveira-DaSilva, A.M., Hedin, C., Stylianou, M.P., Travis, W.D., Matsui, K., Ferrans, V.J., and Moss, J. (2001) Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med, 164, 1072-1076.
36. Taveira-DaSilva, A.M., Stylianou, M.P., Hedin, C.J., Kristof, A.S., Avila, N.A., Rabel, A., Travis, W.D., and Moss, J. (2003) Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am. J. Respir. Crit. CareMed, 168, 1427-1431.
37. Avila, N.A., Dwyer, A.J., Rabel, A., and Moss, J. (2007) Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology, 242, 277-285.
38. Taveira-DaSilva, A.M., Steagall,W.K., and Moss, J. (2006) Lymphangioleiomyomatosis. Cancer Control, 13, 276-285.
39. Lazor, R., Valeyre, D., Lacronique, J., Wallaert, B., Urbane, T., and Cordier, J.F. (2004) Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir. Med, 98, 536-541.
40. Johnson, S.R. and Tattersfield, A.E. (1999) Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am. J. Respir. Crit. Care Med, 160, 628-633.
41. Boehler, A., Speich, R., Russi, E.W., and Weder, W. (1996) Lung transplantation for lymphangioleiomyomatosis. N. Engl. J. Med, 335, 1275-1280.
42. Ryu, J.H., Doerr, C.H., Fisher, S.D., Olson, E.J., and Sahn, S.A. (2003) Chylothorax in lymphangioleiomyomatosis. Chest, 123, 623-627.
43. Roach, E.S., Gomez, M.R., and Northrup, H. (1998) Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol, 13, 624-628.
44. Taveira-DaSilva, A.M., Stylianou, M.P., Hedin, C.J., Hathaway, O., and Moss, J. (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesteron., 126, 1867-1874.
45. Harari, S., Cassandro, R., Chiodini, J., Taveira-DaSilva, A.M., and Moss, J. (2008) Effect of a gonadotrophinreleasing hormone analogue on lung function in lymphangioleiomyomatosi., 133, 448-454.
46. Seyama, K., Kira, S., Takahashi, H., Ohnishi, M., Kodama, Y., Dambara, T., Kobayashi, J., Kitamura, S., and Fukuchi, Y. (2001) Longitudinal follow-up study of 11 patients with pulmonary lymphangioleiomyomatosis: diverse clinical courses of LAM allow some patients to be treated without anti-hormone therap., 6, 331-340.
47. Schiavina, M., Contini, P., Fabiani, A., Cinelli, F., Di Scioscio,V., Zompatori, M., Campidelli, C., and Pileri, S.A. (2007) Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-yearexperience in 36 patients. Sarcoidosis Vasc. Diffuse Lung Dis., 24, 39-50.
48. Banner, A.S., Carrington, C.B., Emory, W.B., Kittle, F., Leonard, G., Ringus, J., Taylor, P., and Addington, W.W. (1981) Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizing leiomyoma. N. Engl. J. Med, 305, 204-209.
49. Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J., Salisbury, S., and Franz, D.N. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med, 358, 140-151.
50. Davies, D.M., Johnson, S.R., Tattersfield, A.E., Kingswood, J.C., Cox, J.A., McCartney, D.L., Doyle, T., Elmslie, F., Saggar, A., de Vries, P.J., and Sampson, J.R. (2008) Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med, 358, 200-203.
51. Bando, K., Paradis, I.L., Keenan, R.J., Yousem, S.A., Komatsu, K., Konishi, H., Guilinger, R.A., Masciangelo, T.N., Pham, S.M., Armitage, J.M. et al. (1995) Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. J. Heart Lung Transplant, 14, 692-698.
52. Nine, J.S., Yousem, S.A., Paradis, I.L., Keenan, R., and Griffith, B.P. (1994) Lymphangioleiomyomatosis: recurrence after lung transplantation. J. Heart Lung Transplant, 13, 714-719.
53. O'Brien, J.D., Lium, J.H., Parosa, J.F., Deyoung, B.R., Wick, M.R., and Trulock, E.P. (1995) Lymphangioleiomyomatosis recurrence in the allograft after single lung transplantatio., 151, 2033-2036.
54. Karbowniczek, M., Astrinidis, A., Balsara, B.R., Testa, J.R., Lium, J.H., Colby, T.V., McCormack, F.X., and Henske, E.P. (2003) Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am. J. Respir. Crit. Care Med, 167, 976-982.
55. Bittmann, I., Rolf, B., Amann, G., and Lohrs, U. (2003) Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum. Pathol, 34, 95-98.
56. Pollock-BarZiv, S., Cohen, M.M., Downey, G.P., Johnson, S.R., Sullivan, E., and McCormack, F.X. (2007) Air travel in women with lymphangioleiomyomatosi., 62, 176-180.
57. Taveira-DaSilva, A.M., Burstein, D., Hathaway, O.M., Fontana, J.R., Gochuico, B.R., Avila, N.A., and Moss, J. (2009) Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosi., 136, 665-670.
58. Hughes, E. and Hodder, R.V. (1987) Pulmonary lymphangiomyomatosis complicating pregnancy. A case report. J. Reprod. Med, 32, 553-557.
59. Shen, A., Iseman, M.D., Waldron, J.A., and King, T.E. (1987) Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogen., 91, 782-785.
60. Wilson, A.M., Slack, H.L., Soosay, S.A., Taylor, T., Carey, F.A., Grove, A., Brown, P.H., and Winter, J.H. (2001) Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states. Scott. Med. J, 46, 150-152.
61. Strizheva, G.D., Carsillo, T., Kruger, W.D., Sullivan, E.J., Ryu, J.H., and Henske, E.P. (2001) The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am. J. Respir. Crit. Care Med, 163, 253-258.
62. Moss, J., DeCastro, R., Patronas, N.J., and Taveira-DaSilva, A. (2001) Meningiomas in lymphangioleiomyomatosis. J. Am. Med. Assoc, 286, 1879-1881.
63. Carsillo, T., Astrinidis, A., and Henske, E.P. (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosi., 97, 6085-6090.
64. Sato, T., Seyama, K., Fujii, H.,Maruyama, H., Setoguchi, Y., Iwakami, S., Fukuchi, Y., and Hino, O. (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J. Hum. Genet., 47, 20-28.
65. Sato, T., Seyama, K., Kumasaka, T., Fujii, H., Setoguchi, Y., Shirai, T., Tomino, Y., Hino, O., and Fukuchi, Y. (2004) Apatient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis. J. Intern. Med., 256, 166-173.
66. Knudson, A.G. (2001) Two genetic hits (more or less) to cance., 1, 157-162.
67. Yu, J., Astrinidis, A., and Henske, E.P. (2001) Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am. J. Respir. Crit. Care Med, 164, 1537-1540.
68. Avila, N.A., Kelly, J.A., Chu, S.C., Dwyer, A.J., and Moss, J. (2000) Lymphangioleiomyomatosis: abdominopelvic CT and US finding., 216, 147-153.
69. Bernstein, S.M., Newell, J.D., Jr., Adamczyk, D., Mortensen, R., King, T.E., Jr., and Lynch, D.A. (1995) How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am. J. Respir. Crit. Care Med, 152, 2138-2143.
70. Smolarek, T.A., Wessner, L.L., McCormack, F.X., Mylet, J.C., Menon, A.G., and Henske, E.P. (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am. J. Hum. Genet, 62, 810-815.
71. Crooks, D.M., Pacheco-Rodriguez, G., DeCastro, R.M., McCoy, J.P., Jr., Wang, J.A., Kumaki, F., Darling, T., and Moss, J. (2004) Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosi., 101, 17462-17467.
72. Goncharova, E.A., Goncharov, D.A.,Spaits, M., Noonan, D.J., Talovskaya, E., Eszterhas, A., and Krymskaya,V.P. (2006) Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am. J. Respir. Cell Mol. Biol, 34, 561-572.
73. Goncharova, E.A., Goncharov, D.A., Lim, P.N., Noonan, D., and Krymskaya, V.P. (2006) Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol, 34, 473-480.
74. El-Hashemite, N., Zhang, H., Henske, E.P., and Kwiatkowski, D.J. (2003) Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipom., 361, 1348-1349.
75. Robb, V.A., Astrinidis, A., and Henske, E.P. (2006) Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas. Mod. Pathol, 19, 839-846.
76. Karbowniczek, M., Cash, T., Cheung, M., Robertson, G.P., Astrinidis, A., and Henske, E.P. (2004) Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem, 279, 29930-29937.
77. Karbowniczek, M., Robertson, G.P., and Henske, E.P. (2006) Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J. Biol. Chem, 281, 25447-25456.
78. Finlay, G.A., Malhowski, A.J., Liu, Y., Fanburg, B.L., Kwiatkowski, D.J., and Toksoz, D. (2007) Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res, 67, 9878-9886.
79. Juvet, S.C., McCormack, F.X., Kwiatkowski, D.J., and Downey, G.P. (2007) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am. J. Respir. Cell Mol. Biol., 36, 398-408.
80. Lim, S.D., Stallcup, W., Lefkove, B., Govindarajan, B., Au, K.S., Northrup, H., Lang, D., Fisher, D.E., Patel, A., Amin, M.B., and Arbiser, J.L. (2007) Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol. Med, 13, 160-165.
81. Kumasaka, T., Seyama, K., Mitani, K., Souma, S., Kashiwagi, S., Hebisawa, A., Sato, T., Kubo, H., Gomi, K., Shibuya, K., Fukuchi, Y., and Suda, K. (2005) Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am. J. Surg. Pathol, 29, 1356-1366.
82. Bonetti, F., Pea, M., Martignoni, G., Doglioni, C., Zamboni, G., Capelli, P., Rimondi, P., and Andrion, A. (1994) Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma: the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC., 26, 230-236.
83. Folpe, A.L., Mentzel, T., Lehr, H.A., Fisher, C., Balzer, B.L., and Weiss, S.W. (2005) Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am. J. Surg. Pathol, 29, 1558-1575.
84. Hornick, J.L. and Fletcher, C.D. (2006) PEComa: what do we know so far? Histopathology, 48, 75-82.
85. Henry, K.W., Yuan, X., Koszewski, N.J., Onda, H., Kwiatkowski, D.J., and Noonan, D.J. (1998) Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J. Biol. Chem, 273, 20535-20539.
86. Noonan, D.J., Lou, D., Griffith, N., and Vanaman, T.C. (2002) A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch. Biochem. Biophys, 398, 132-140.
87. Finlay, G.A., York, B., Karas, R.H., Fanburg, B.L., Zhang, H., Kwiatkowski, D.J., and Noonan, D.J. (2004) Estrogeninduced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J. Biol. Chem, 279, 23114-23122.
88. York, B., Lou, D., Panettieri, R.A., Jr., Krymskaya, V.P., Vanaman, T.C., and Noonan, D.J. (2005) Cross-talk between tuberin, calmodulin, and estrogen signaling pathways. FASEB J, 19, 1202-1204.
89. Yu, J., Astrinidis, A., Howard, S., and Henske, E.P. (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathway., 286, L694-L700.
90. Yu, J. and Henske, E.P. (2006) Estrogeninduced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res, 66, 9461-9466.
91. Matsui, K., Takeda, K., Yu, Z.X., Travis, W.D., Moss, J., and Ferrans, V.J. (2000) Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch. Pathol. Lab. Med, 124, 267-275.
92. Zhe, X., Yang, Y., and Schuger, L. (2005) Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am. J. Respir. Cell Mol. Biol, 32, 28-34.
93. Zhe, X., Yang, Y., Jakkaraju, S., and Schuger, L. (2003) Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am. J. Respir. Cell Mol. Biol, 28, 504-511.
94. Birt, A.R., Hogg, G.R., and Dube, W.J. (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol., 113, 1674-1677.
95. Toro, J.R., Glenn, G., Duray, P., Darling, T.,Weirich, G., Zbar, B., Linehan, M., and Turner, M.L. (1999) Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch. Dermatol, 135, 1195-1202.
96. Zbar, B., Alvord,W.G., Glenn, G., Turner, M., Pavlovich, C.P., Schmidt, L.,Walther, M., Choyke, P.,Weirich, G.,Hewitt, S.M., Duray, P., Gabril, F., Greenberg, C., Merino, M.J., Toro, J., and Linehan,W.M. (2002) Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol. Biomarkers Prev, 11, 393-400.
97. Nickerson, M.L., Warren, M.B., Toro, J.R., Matrosova, V., Glenn, G., Turner, M.L., Duray, P., Merino, M., Choyke, P., Pavlovich, C.P., Sharma, N.,Walther, M., Munroe, D., Hill, R., Maher, E., Greenberg, C., Lerman, M.I., Linehan, W.M., Zbar, B., and Schmidt, L.S. (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrom., 2, 157-164.
98. van Slegtenhorst, M., Khabibullin, D., Hartman, T.R., Nicolas, E., Kruger,W.D., and Henske, E.P. (2007) The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. J. Biol. Chem, 282, 24583-24590.
99. Baba, M., Hong, S.B., Sharma, N., Warren, M.B., Nickerson, M.L., Iwamatsu, A., Esposito, D.,Gillette,W.K., Hopkins, R.F., 3rd, Hartley, J.L., Furihata, M., Oishi, S., Zhen, W., Burke, T.R., Jr., Linehan, W.M., Schmidt, L.S., and Zbar, B. (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signalin., 103, 15552-15557.
100. Baba, M., Furihata, M., Hong, S.B., Tessarollo, L., Haines, D.C., Southon, E., Patel, V., Igarashi, P., Alvord, W.G., Leighty, R., Yao, M., Bernardo, M., Ileva, L., Choyke, P., Warren, M.B., Zbar, B., Linehan, W.M., and Schmidt, L.S. (2008) Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J. Natl. Cancer Inst, 100, 140-154.
101. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol, 14, 1296-1302.
102. Lee, L., Sudentas, P., and Dabora, S.L. (2006) Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis comple., 45, 933-944.
103. Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M.S., El-Hashemite, N., Lader, A.S., Onda, H., Zhang, H., Kwiatkowski, D.J., and Dabora, S.L. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse model., 42, 213-227.
104. McCormack, F.X. and Moss, J. (2007) S-LAM in a man? Am. J. Respir. Crit. Care Med, 176, 3-5.
105. Crino, P.B., Nathanson, K.L., and Henske, E.P. (2006) The tuberous sclerosis complex. N. Engl. J. Med, 355, 1345-1356.